MacroGenics, Victoria University, University of Kansas, NIH, Cox Communications | GenomeWeb

MacroGenics Closes $30.5M Series B VC Round

MacroGenics, a Rockville, Md.-based firm that develops therapeutic antibodies for use in the treatment of various cancers and inflammatory diseases, has collected $30.5 million in a Series B round of private-equity financing, the company said last week.

MacroGenics lists Institute for Systems Biology co-founders Lee Hood, Alan Aderem, and Ruedi Aebersold among its founders, as well as Jeffrey Ravetch from Rockefeller University.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Japan Times says regulations are needed to oversee human genome-editing research.

In PNAS this week: mutations linked to nasopharyngeal carcinoma, salivary proteins common among oral squamous cell carcinoma patients, and more.

At Wired, a science journalist discusses her decision not to undergo BRCA testing.

In PLOS this week: molecular surveillance of S. Typhi, genome-wide association study of attention in children, and more.